Should perindopril be continued in a CKD patient (eGFR decreased from 29 to 27 mL/min/1.73 m² and proteinuria reduced from 1.9 g to ~1 g per day) who is already taking allopurinol, doxazosin, and Loma.to (presumed renin‑angiotensin system blocker)?

Should Perindopril Be Continued in This CKD Patient?

Yes, perindopril should absolutely be continued—the modest 2 mL/min/1.73 m² eGFR decline from 29 to 27 is well within the acceptable 30% threshold, and the dramatic 47% reduction in proteinuria (from 1.9 g to 1 g daily) demonstrates excellent therapeutic response that will reduce long-term mortality and cardiovascular risk. 1

Why This eGFR Decline Is Expected and Safe

• KDIGO 2024 explicitly states that ACE inhibitors or ARBs should be continued unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase—this patient's creatinine change is far below that threshold. 1

• The 2 mL/min/1.73 m² decline represents approximately a 7% decrease in eGFR, which reflects the expected hemodynamic adjustment when RAS inhibition reduces intraglomerular pressure; this initial dip is actually associated with long-term renoprotection rather than harm. 1, 2

• KDIGO Practice Point 3.6.7 unequivocally directs clinicians to continue ACE inhibitors or ARBs in people with CKD even when eGFR falls below 30 mL/min per 1.73 m², meaning this patient at eGFR 27 should remain on perindopril. 1, 3

The Proteinuria Reduction Is Clinically Significant

• The reduction from 1.9 g to 1 g per day represents a 47% decrease in proteinuria, which is a powerful predictor of slowed CKD progression and reduced cardiovascular mortality. 4, 5

• Patients with proteinuria >700 mg/g (this patient started at 1900 mg/day) face a 5.83-fold increased risk of cardiorenal hospitalization and 2.89-fold increased all-cause mortality compared to those with minimal proteinuria—achieving a 47% reduction directly addresses this excess risk. 4

• In a 1997 study of perindopril in nephrotic-range proteinuria, 50% of responders achieved reductions from 6.1 g/24h to 1.2 g/24h, with sustained benefit for up to 2 years of continuous therapy. 6

Monitoring Parameters Going Forward

• Recheck serum creatinine, eGFR, and potassium 2–4 weeks after any dose adjustment of perindopril or concurrent diuretics (doxazosin is an alpha-blocker, not a diuretic, so the patient may or may not be on a diuretic). 1

• If hyperkalemia develops, manage it with dietary potassium restriction, diuretics (if not already prescribed), or potassium binders rather than stopping perindopril—KDIGO Practice Point 3.6.3 emphasizes that hyperkalemia should be managed medically rather than by dose reduction or discontinuation of RAS inhibition. 1, 3

• Only consider reducing or discontinuing perindopril if: (1) creatinine rises >30% within 4 weeks, (2) symptomatic hypotension occurs despite conservative measures, or (3) uncontrolled hyperkalemia persists despite medical treatment. 1, 2

Dose Optimization

• The FDA label for perindopril states that in patients with creatinine clearance >30 mL/min (this patient is at eGFR 27, which approximates CrCl ~27–30), the initial dose should be 2 mg/day and should not exceed 8 mg/day—this patient is currently on 2 mg twice daily (4 mg total), which is within the safe range. 7

• KDIGO Practice Point 3.6.1 recommends using the highest approved dose of ACE inhibitor or ARB that is tolerated, so if blood pressure and potassium remain stable over the next 2–4 weeks, consider maintaining or cautiously up-titrating rather than reducing the dose. 1, 3

Additional Renoprotective Therapies to Consider

• If this patient has type 2 diabetes and eGFR ≥20 mL/min/1.73 m², KDIGO gives a strong (1A) recommendation to add an SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin) for additional kidney and cardiovascular protection. 1, 3

• Even without diabetes, if the patient has urine albumin-to-creatinine ratio ≥200 mg/g or heart failure, SGLT2 inhibitors are strongly recommended (1A) for eGFR ≥20 mL/min/1.73 m²—this patient's proteinuria of 1 g/day likely corresponds to UACR >200 mg/g. 1, 3

• For patients with type 2 diabetes, eGFR >25 mL/min/1.73 m², normal potassium, and persistent albuminuria despite maximal RAS inhibition, KDIGO suggests adding a nonsteroidal mineralocorticoid receptor antagonist (e.g., finerenone) as third-line therapy. 1, 3

Common Pitfalls to Avoid

• Do not discontinue perindopril based solely on a modest eGFR decline—the 7% decrease is hemodynamic, expected, and does not indicate drug toxicity or accelerated kidney injury. 1, 2

• Do not switch to a calcium-channel blocker (e.g., amlodipine) monotherapy—this would forfeit the proven renoprotective and antiproteinuric benefits of RAS inhibition, which are independent of blood pressure lowering. 2

• Do not combine perindopril with another RAS inhibitor (ARB or direct renin inhibitor)—KDIGO Recommendation 3.6.4 explicitly advises against any combination of ACE inhibitor + ARB + direct renin inhibitor due to increased risk of hyperkalemia, hypotension, and acute kidney injury without added benefit. 1, 3, 2

• Do not stop perindopril if eGFR continues to decline below 27 mL/min/1.73 m²—KDIGO directs continuation even as eGFR falls below 30, and only consider discontinuation when eGFR drops below 15 mL/min/1.73 m² with symptomatic uremia, hypotension, or uncontrolled hyperkalemia. 1, 3, 2